Drugs

High response rates in poor-risk population – Hagop Kantarjian

Photo of Dr. Hagop Kantarjian from obroncology.com

Jul 22, 2023, 17:56

High response rates in poor-risk population – Hagop Kantarjian

Our study of aza + ven + pevonedistat NEDD8-activating enzyme inhibitor in secondary AML & MDS/CMML after HMA failure. High response rates in poor-risk population. Data from randomized ph3 study in AML are awaited.

For article: Click here

Source: Hagop Kantarjian/Twitter

cancer Hagop Kantarjian Leukemia OncoDaily Oncology pevonedistat Research

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Special Coverage

ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023

Facebook

RSS Feed

Youtube

Blog

Feb 21, 2025, 15:06

The full press release of ELLOK is out

Blog

Feb 21, 2025, 14:59

Siobhan Freeney: What women in Ireland need to know about Dense Breasts and Cancer

Blog

Feb 21, 2025, 14:54

CEO of the Canadian Cancer Society about the inequities in cancer care across populations in Canada - UICC

Career

Feb 21, 2025, 14:34

Kristiyana Kaneva is appointed as Medical Director of Oncology Early Development at AbbVie

Blog

Feb 21, 2025, 14:27

Douglas Flora: A Cure for Cancer - Closer Than We Think?

Blog

Feb 21, 2025, 14:26

14th Biennial Childhood Leukemia and Lymphoma Symposium: Advancing Research and Collaboration in Budapest

Blog

Feb 21, 2025, 14:13

Rachel Chown: An incredibly inspiring and humbling talk from Liubov Lisovska

Science

Feb 21, 2025, 14:08

Survival improvement of patients with melanoma brain or leptomeningeal metastases in Denmark - CCIT-DK

Science

Feb 21, 2025, 13:51

Aaron Sverdlov: Identifying common pathways for doxorubicin and carfilzomib-induced cardiotoxicities

Blog

Feb 21, 2025, 13:40

Breaking barriers: ensuring equal cancer care access for diverse communities - SPCC

Blog

Feb 21, 2025, 13:29

Sana Al Sukhun: Enjoyed joining Emirates Oncology Society's SABCS

Blog

Feb 21, 2025, 13:28

Targeted protein degradation is changing the landscape of cancer treatment - The ICR